{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:35:13Z","timestamp":1794587713302,"version":"4.9.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["5P50 AG005131-31"],"award-info":[{"award-number":["5P50 AG005131-31"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["5T35HL007491"],"award-info":[{"award-number":["5T35HL007491"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1U01NS086659"],"award-info":[{"award-number":["1U01NS086659"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1U54NS092089-01"],"award-info":[{"award-number":["1U54NS092089-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014275","name":"Parkinson Study Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AVID Pharmaceuticals"},{"name":"Abbvie\/C2N Diagnostics"},{"name":"Biogen\/Bristol-Myers Squibb studies"},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"TEVA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bial"},{"name":"Accorda"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Solvay"},{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Network for Research on Neurodegenerative Disorders"},{"DOI":"10.13039\/501100004587","name":"Instituto Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Michael J. Fox Foundation for Parkinson\u2019s Researc"},{"name":"Fondo de Investigaciones Sanitarias de la Seguridad Social"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.parkreldis.2019.07.010","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:30:59Z","timestamp":1562671859000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability"],"prefix":"10.1016","volume":"66","author":[{"given":"Ali","family":"Shoeibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-3445","authenticated-orcid":false,"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9806-7083","authenticated-orcid":false,"given":"Teodoro del","family":"Ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euyhyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.parkreldis.2019.07.010_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"Steele","year":"1964","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.07.010_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jnnp.37.2.121","article-title":"Thesubcortical dementia'of progressive supranuclear palsy","volume":"37","author":"Albert","year":"1974","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.07.010_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.07.010_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.07.010_bib5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.07.010_bib6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: richardson's syndrome and PSP-parkinsonism","volume":"128","author":"Williams","year":"2005","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.parkreldis.2019.07.010_bib7","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00415-014-7384-x","article-title":"Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study","volume":"261","author":"Jecmenica-Lukic","year":"2014","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.07.010_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK\u20103 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.07.010_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/mds.25815","article-title":"Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial","volume":"29","author":"H\u00f6glinger","year":"2014","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.parkreldis.2019.07.010_bib10","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/mds.21698","article-title":"Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy","volume":"22","author":"Williams","year":"2007","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.07.010_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mds.10459","article-title":"SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders","volume":"18","author":"Litvan","year":"2003","journal-title":"Mov. Disord."},{"issue":"14","key":"10.1016\/j.parkreldis.2019.07.010_bib12","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases","volume":"29","author":"Respondek","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.07.010_bib13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/mds.25327","article-title":"Accuracy of the National Institute for Neurological Disorders and Stroke\/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy","volume":"28","author":"Respondek","year":"2013","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.07.010_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2019.07.010_bib15","series-title":"Dementia Rating Scale-2: Professional Manual","author":"Mattis","year":"2001"},{"issue":"11","key":"10.1016\/j.parkreldis.2019.07.010_bib16","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB A frontal assessment battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.parkreldis.2019.07.010_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/jnp.4.2.134","article-title":"Reliability, validity, and clinical correlates of apathy in Parkinson's disease","volume":"4","author":"Starkstein","year":"1992","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2019.07.010_bib18","series-title":"EQ-5D-3L User Guide. Basic Information on How to Use the EQ-5D-5L Instrument Rotterdam","first-page":"22","author":"Rabin","year":"2011"},{"key":"10.1016\/j.parkreldis.2019.07.010_bib19","series-title":"Third Symposium on Parkinson's Disease Research","first-page":"152","article-title":"Projection technique for evaluating surgery in Parkinson's disease","author":"Schwab","year":"1969"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.07.010_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","article-title":"The unified Parkinson's disease rating scale (UPDRS): status and recommendations","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease","year":"2003","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.07.010_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.parkreldis.2019.07.010_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.04.014","article-title":"Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials","volume":"28","author":"Bang","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.07.010_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.07.010_bib24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/mds.26973","article-title":"Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019303001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019303001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:18:01Z","timestamp":1761178681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019303001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":24,"alternative-id":["S1353802019303001"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.010","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}